As the quest for a Zika vaccine unfolds, Inovio Pharma ($INO) continues to lead the pack. The Pennsylvania-based vaccine maker announced Monday that its candidate showed promise in nonhuman primates.
The company’s synthetic DNA vaccine elicited “robust” antibody and T cell responses in monkeys, Inovio said in a statement. Each animal that received two doses of the vaccine developed antibodies against the mosquito-borne disease. Three months ago, Inovio reported that the candidate performed well in mice.
Read more here